臨床微生物学市場：製品タイプ、検体タイプ、エンドユーザー、用途別-2025-2030年の世界予測

臨床微生物学市場は、2023年に78億米ドルと評価され、2024年には86億8,000万米ドルに達すると予測され、CAGR 10.91％で成長し、2030年には161億2,000万米ドルに達すると予測されています。

臨床微生物学の対象範囲には、細菌、ウイルス、真菌、寄生虫など、ヒトに病気を引き起こす微生物の研究と応用が含まれます。その必要性は、公衆衛生への関心の高まり、抗生物質耐性、迅速な診断・治療ソリューションの必要性から生じています。主な用途は、診断、感染予防と制御、抗菌薬感受性検査で、病院、診断ラボ、バイオテクノロジー企業にサービスを提供しています。主な市場成長要因としては、分子診断学の進歩、感染症の流行増加、病気の蔓延を抑えるための政府の取り組みなどが挙げられます。ポイント・オブ・ケア検査に対する需要の高まりと、病原体の検出と分類における技術革新は、大きなビジネスチャンスをもたらしています。例えば、電気化学や光学バイオセンサーを診断に活用することで、競合優位性が得られる可能性があります。しかし、新興国市場は、高度な診断技術の高コスト、熟練した人材の不足、厳しい規制の枠組みといった限界に直面しており、これが開発と普及の妨げとなっています。さらに、病原菌の突然変異率が速いため、診断精度と治療効果の安定性に課題があります。利害関係者にとっては、研修イニシアティブへの投資や規制の調和を追求することにより、これらの限界に対処することが極めて重要です。イノベーションは、迅速診断技術の強化、低リソース環境向けの手頃なソリューションの開発、予測診断のためのビッグデータ解析の活用によって推進することができます。ゲノムシークエンシング、AI主導の診断ツール、個別化医療の研究が進めば、実質的な成長の道が開ける。市場はダイナミックな性質を示し、学界、産業界、ヘルスケア施設間の協力的な取り組みが増加し、競争圧力を背景にイノベーションが促進されています。企業は、持続可能な成長と市場浸透を確実にするため、研究開発への戦略的投資、技術共有のためのパートナーシップの重視、医療インフラは不十分だが需要は伸びているという特徴を持つ未開拓の地域市場の開拓を行うことが推奨されます。

市場力学：急速に進化する臨床微生物学市場の主要市場インサイトを公開

臨床微生物学市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症の管理と制御における臨床微生物学の使用の増加
  • がんの診断および研究における政府および民間組織の支援およびイニシアティブの促進
• 市場抑制要因
  • 熟練した専門家、設備、インフラの不足
• 市場機会
  • 臨床微生物学製品およびプロセスの技術的進歩
  • ポイントオブケア微生物検査のイントロダクション
• 市場の課題
  • 臨床微生物学ラボの品質保証と管理に関する問題

ポーターの5つの力：臨床微生物学市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：臨床微生物学市場における外部からの影響の把握

外部マクロ環境要因は、臨床微生物学市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析臨床微生物学市場における競合情勢の把握

臨床微生物学市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス臨床微生物学市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、臨床微生物学市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の管理と制御における臨床微生物学の使用の増加
    • がんの診断と調査に対する政府と民間団体の好意的な支援と取り組み
  • 抑制要因
    • 熟練した専門家、設備、インフラの不足
  • 機会
    • 臨床微生物学製品およびプロセスにおける技術的進歩
    • ポイントオブケア微生物検査のイントロダクション
  • 課題
    • 臨床微生物学研究室における品質保証と管理に関する問題
• 市場セグメンテーション分析
  • 製品：臨床微生物学評価における実験器具の使用
  • 検体の種類：過去または現在の感染を検出するための血清学的検査では血清サンプルが優先されます
  • エンドユーザー：感染症の病状に関する詳細な情報を提供するために、研究室や研究所で臨床微生物学を採用する
  • 応用：原因となる病原体を特定することで、胃腸疾患を診断するための臨床微生物学の使用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 臨床微生物学市場：製品別

• 機器
• 試薬

第7章 臨床微生物学市場標本の種類別

• 血
• 体液
• 脳脊髄液
• 糞便
• 唾液
• 血清
• 滑液
• 尿

第8章 臨床微生物学市場：エンドユーザー別

• 学術調査機関
• 病院と介護サービス提供者
• 研究所

第9章 臨床微生物学市場：用途別

• 自己免疫疾患
• 心臓病学
• 糖尿病
• 薬物検査
• 消化器疾患
• 腎臓学
• 腫瘍学
• 歯周病
• 呼吸器疾患
• 性感染症

第10章 南北アメリカの臨床微生物学市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の臨床微生物学市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの臨床微生物学市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ウィチタ州立大学のMDL研究所が微生物学へ移行。
  • ケンブリッジのスタートアップ企業が新たな診断法の開発資金を獲得。
  • 微生物学会とインド科学研究所バンガロール校の間で変革協定が締結
  • Hardy Diagnostics社、Premier社と手動微生物学契約を締結
  • 医療微生物学科が総額680万米ドルの4つの新プロジェクトと新しいウェブサイトを公開。
  • ASMが包括的微生物学リーダープログラムに資金提供。
  • MAESTRIAは、Biomerieuxが開発した、研究室のワークフローを最適化し、患者ケアを改善する新世代の微生物学ミドルウェアです。
  • Beckman Coulter社とMeMed社は、ウイルス感染と細菌感染を区別できる実証済みの宿主免疫応答診断へのアクセスを拡大します。
  • BDが微生物学研究室向けに完全自動化ロボットトラックシステムを導入。
  • FASTinovはBeckman Coulter Life Sciencesと提携し、臨床微生物学ラボに超高速2h-ASTの革新的なテクノロジーを導入します。
  • アップステートは、ライム病およびダニ媒介性疾患の多分野にわたる治療センターの開設を計画しています。
  • Bio-RadがAbbott診断プラットフォームのQC範囲を拡大。
  • 連邦政府の資金により、アルバータ大学の感染力の高い病原体への対応能力が強化される予定。
  • オックスフォード大学、ヘルスケア調査のために1億2,200万ポンド（1億3,663万米ドル）の資金を獲得。
  • Sci-Tech DaresburyのPerfectus Biomed Groupが、医療機器試験の世界的リーダーであるNAMSAに買収されました。
  • HORIBA Veterinary、診断が難しい寄生虫を検査する新たな迅速PCR検査を追加。
  • ValitaCellがBeckman Coulter Life Sciencesに加わりました。
  • Global Access DiagnosticsがBio-Rad LaboratoriesからIT-LEISH迅速診断テストの製造権を取得。
  • SSI Diagnosticaは力強い成長を続けています。
  • BDとAccelerate Diagnosticsが世界の商業提携を発表。
  • SGSはアリゾナ州フェニックスに新しい微生物学研究所を開設しました。
  • イスラエル：イスラエルの微生物診断企業PocaredにEUが2,200万ユーロ（2,426万米ドル）を援助。
  • DCN Dxが微生物学的検査製品会社Biomed Diagnosticsを買収。
  • bioMerieuxは、迅速なASTソリューションに重点を置く革新的企業であるSpecific Diagnosticsを買収し、抗菌薬耐性と戦う取り組みを強化しました。
  • NIHが新しい結核調査推進センターに資金提供。
  • RaueがSonicヘルスケアによるDiagnosticum Laboratory Groupの買収について助言。
  • ATCCは、QIAGENとの提携によりバイオインフォマティクスデータプラットフォームを拡張することを発表しました。
  • Hardy DiagnosticsがBioCode MDx-3000の提供を開始しました。
  • メルクは、CDMOの提供を強化し、将来の成長を加速するために、ライフサイエンス事業部門の組織改革を発表しました。
  • COPAN Diagnosticsは、臨床微生物学における人工知能の進化における新たな大きな一歩を発表しました。

企業一覧

• ELITech Group
• Beckman Coulter, Inc.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Rapid Micro Biosystems, Inc.
• Kyokuto Pharmaceutical Industrial Co., Ltd.
• Hardy Diagnostics
• SSI Diagnostica A/S
• QIAGEN N.V.
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Liofilchem S.r.l.
• 3M Company
• Bio-Rad Laboratories, Inc.
• bioMerieux S.A.
• Abbott Laboratories
• COPAN Diagnostics Inc.
• Cardinal Health, Inc.
• Vircell S.L.
• TCS Biosciences Ltd.
• Clinichem Ltd.
• Advanced Instruments, LLC
• B. Braun SE
• Pro Lab Diagnostics Inc.
• Prestige Diagnostics U.K. Ltd.
• Laboratorios Conda, S.A.
• Becton, Dickinson and Company
• Shimadzu Corporation
• HORIBA, Ltd.
• Diagnostica Longwood S.L.

LIST OF FIGURES

• FIGURE 1. CLINICAL MICROBIOLOGY MARKET RESEARCH PROCESS
• FIGURE 2. CLINICAL MICROBIOLOGY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CLINICAL MICROBIOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CLINICAL MICROBIOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CLINICAL MICROBIOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CLINICAL MICROBIOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY BODY FLUIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY CEREBROSPINAL SPINAL FLUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY FECAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SYNOVIAL FLUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY DRUG TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY PERIODONTAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CLINICAL MICROBIOLOGY MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CLINICAL MICROBIOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. CHINA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. CHINA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. INDIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. JAPAN CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. MALAYSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. MALAYSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. PHILIPPINES CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. PHILIPPINES CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 91. PHILIPPINES CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. PHILIPPINES CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SINGAPORE CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. SINGAPORE CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 95. SINGAPORE CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. SINGAPORE CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. SOUTH KOREA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. SOUTH KOREA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 99. SOUTH KOREA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. SOUTH KOREA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. TAIWAN CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. TAIWAN CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 103. TAIWAN CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. TAIWAN CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. THAILAND CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. THAILAND CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 107. THAILAND CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. THAILAND CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. VIETNAM CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. VIETNAM CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 111. VIETNAM CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. VIETNAM CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 118. DENMARK CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. DENMARK CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 120. DENMARK CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. DENMARK CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. EGYPT CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. EGYPT CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 124. EGYPT CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. EGYPT CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. FINLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. FINLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 128. FINLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. FINLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. FRANCE CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. FRANCE CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 132. FRANCE CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. FRANCE CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. GERMANY CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. GERMANY CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 136. GERMANY CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. GERMANY CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. ISRAEL CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. ISRAEL CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 140. ISRAEL CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. ISRAEL CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. ITALY CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. ITALY CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 144. ITALY CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. ITALY CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. NETHERLANDS CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. NETHERLANDS CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 148. NETHERLANDS CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. NETHERLANDS CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. NIGERIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. NIGERIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 152. NIGERIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. NIGERIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. NORWAY CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. NORWAY CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 156. NORWAY CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. NORWAY CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. POLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. POLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 160. POLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. POLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. QATAR CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. QATAR CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 164. QATAR CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. QATAR CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. RUSSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. RUSSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 168. RUSSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. RUSSIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. SAUDI ARABIA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. SAUDI ARABIA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SAUDI ARABIA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SAUDI ARABIA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH AFRICA CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. SPAIN CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 179. SPAIN CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SPAIN CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. SPAIN CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. SWEDEN CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. SWEDEN CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 184. SWEDEN CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. SWEDEN CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. SWITZERLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. SWITZERLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 188. SWITZERLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. SWITZERLAND CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. TURKEY CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. TURKEY CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 192. TURKEY CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. TURKEY CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. UNITED ARAB EMIRATES CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. UNITED KINGDOM CLINICAL MICROBIOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 199. UNITED KINGDOM CLINICAL MICROBIOLOGY MARKET SIZE, BY SPECIMEN TYPE, 2018-2030 (USD MILLION)
• TABLE 200. UNITED KINGDOM CLINICAL MICROBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. UNITED KINGDOM CLINICAL MICROBIOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. CLINICAL MICROBIOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 203. CLINICAL MICROBIOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

The Clinical Microbiology Market was valued at USD 7.80 billion in 2023, expected to reach USD 8.68 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 16.12 billion by 2030.

The scope of clinical microbiology encompasses the study and application of microorganisms causing diseases in humans, spanning bacteria, viruses, fungi, and parasites. Its necessity arises from growing public health concerns, antibiotic resistance, and the need for rapid diagnostic and therapeutic solutions. Applications are primarily in diagnostics, infection prevention and control, and antimicrobial susceptibility testing, serving hospitals, diagnostic labs, and biotechnology companies. Key market growth factors include advancements in molecular diagnostics, increased prevalence of infectious diseases, and government initiatives to curb disease spread. The rising demand for point-of-care testing and technological innovation in detecting and categorizing pathogens offers significant opportunities. For instance, leveraging electrochemical and optical biosensors in diagnostics could provide competitive advantages. The market, however, faces limitations such as high costs of advanced diagnostic techniques, a shortage of skilled personnel, and stringent regulatory frameworks that can impede development and rollout. Moreover, the rapid mutation rates of pathogens present challenges for consistent diagnostic accuracy and therapeutic efficacy. It's pivotal for stakeholders to address these limitations by investing in training initiatives and pursuing regulatory harmonization. Innovation can be driven by enhancing rapid diagnostic technologies, developing affordable solutions for low-resource settings, and harnessing big data analytics for predictive diagnostics. Further research into genome sequencing, AI-driven diagnostic tools, and personalized medicine can provide substantive growth avenues. The market exhibits a dynamic nature with increasing collaborative efforts between academia, industry, and healthcare facilities, fostering innovation against a backdrop of competitive pressures. Businesses are recommended to invest strategically in R&D, focus on partnerships for technology sharing, and explore untapped regional markets characterized by inadequate health infrastructure but growing demand, to ensure sustainable growth and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Microbiology Market

The Clinical Microbiology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing use of clinical microbiology in managing and controlling infectious diseases
  • Favorable government and private organizations support, and initiatives in cancer diagnosis and research
• Market Restraints
  • Limited availability of skilled professionals, equipment and infrastructure
• Market Opportunities
  • Technological advancement in clinical microbiology products and processes
  • Introduction of point-of-care microbiology testing
• Market Challenges
  • Problems concerning quality assurance and management in clinical microbiology laboratories

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Microbiology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Microbiology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Microbiology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Microbiology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Microbiology Market

A detailed market share analysis in the Clinical Microbiology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Microbiology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Microbiology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Clinical Microbiology Market, highlighting leading vendors and their innovative profiles. These include ELITech Group, Beckman Coulter, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Rapid Micro Biosystems, Inc., Kyokuto Pharmaceutical Industrial Co., Ltd., Hardy Diagnostics, SSI Diagnostica A/S, QIAGEN N.V., Merck KGaA, F. Hoffmann-La Roche Ltd., Liofilchem S.r.l., 3M Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Abbott Laboratories, COPAN Diagnostics Inc., Cardinal Health, Inc., Vircell S.L., TCS Biosciences Ltd., Clinichem Ltd., Advanced Instruments, LLC, B. Braun SE, Pro Lab Diagnostics Inc., Prestige Diagnostics U.K. Ltd., Laboratorios Conda, S.A., Becton, Dickinson and Company, Shimadzu Corporation, HORIBA, Ltd., and Diagnostica Longwood S.L..

Market Segmentation & Coverage

This research report categorizes the Clinical Microbiology Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments and Reagents.
• Based on Specimen Type, market is studied across Blood, Body fluids, Cerebrospinal Spinal Fluid, Fecal, Saliva, Serum, Synovial Fluid, and Urine.
• Based on End-User, market is studied across Academic & Research Institutes, Hospitals & Care Providers, and Laboratories.
• Based on Application, market is studied across Autoimmune Diseases, Cardiology, Diabetes, Drug Testing, Gastrointestinal Diseases, Nephrology, Oncology, Periodontal Diseases, Respiratory Diseases, and Sexually Transmitted Diseases.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing use of clinical microbiology in managing and controlling infectious diseases
    • 5.1.1.2. Favorable government and private organizations support, and initiatives in cancer diagnosis and research
  • 5.1.2. Restraints
    • 5.1.2.1. Limited availability of skilled professionals, equipment and infrastructure
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement in clinical microbiology products and processes
    • 5.1.3.2. Introduction of point-of-care microbiology testing
  • 5.1.4. Challenges
    • 5.1.4.1. Problems concerning quality assurance and management in clinical microbiology laboratories
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Use of laboratory instruments in clinical microbiology assessments
  • 5.2.2. Specimen Type: Preference for serum samples in serological testing to detect past or current infections
  • 5.2.3. End-User: Adoption of clinical microbiology in laboratories and research institutes to provide detailed insights about infectious disease conditions
  • 5.2.4. Application: Increasing use of clinical microbiology to diagnose gastrointestinal (GI) diseases by identifying causative pathogens
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Clinical Microbiology Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents

7. Clinical Microbiology Market, by Specimen Type

• 7.1. Introduction
• 7.2. Blood
• 7.3. Body fluids
• 7.4. Cerebrospinal Spinal Fluid
• 7.5. Fecal
• 7.6. Saliva
• 7.7. Serum
• 7.8. Synovial Fluid
• 7.9. Urine

8. Clinical Microbiology Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Hospitals & Care Providers
• 8.4. Laboratories

9. Clinical Microbiology Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Diseases
• 9.3. Cardiology
• 9.4. Diabetes
• 9.5. Drug Testing
• 9.6. Gastrointestinal Diseases
• 9.7. Nephrology
• 9.8. Oncology
• 9.9. Periodontal Diseases
• 9.10. Respiratory Diseases
• 9.11. Sexually Transmitted Diseases

10. Americas Clinical Microbiology Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Clinical Microbiology Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Clinical Microbiology Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Wichita State's MDL Lab Shifting To Microbiology.
  • 13.3.2. Cambridge Start-Up Won Funding To Develop New Diagnostics.
  • 13.3.3. Transformative Agreement Signed Between The Microbiology Society And Indian Institute Of Science Bangalore
  • 13.3.4. Hardy Diagnostics Awarded Manual Microbiology Agreement With Premier, Inc.
  • 13.3.5. Department of Medical Microbiology Unveils Four New Projects Worth USD 6.8 Million and New Website.
  • 13.3.6. ASM Funded for Inclusive Microbiology Leaders Program.
  • 13.3.7. MAESTRIA, A New Generation Microbiology Middleware Developed by Biomerieux to Optimize Laboratory Workflow and Improve Patient Care.
  • 13.3.8. Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Viral and Bacterial Infections.
  • 13.3.9. BD Introduces Fully Automated Robotic Track System for Microbiology Labs.
  • 13.3.10. FASTinov Collaborates with Beckman Coulter Life Sciences to Bring Ultra-Rapid 2h-AST Disruptive Technology to Clinical Microbiology Laboratories.
  • 13.3.11. Upstate Planned To Launch A Multidisciplinary Lyme And Tick-Borne Disease Treatment Center.
  • 13.3.12. Bio-Rad Expands QC Range for Abbott Diagnostic Platforms.
  • 13.3.13. Federal Funds Set To Boost U of A's Ability To Handle Highly Infectious Pathogens.
  • 13.3.14. Oxford Gets £122m (USD 136.63 Million) Funding for Healthcare Research.
  • 13.3.15. Sci-Tech Daresbury's Perfectus Biomed Group Acquired by Global Medical Device Testing Leader NAMSA.
  • 13.3.16. HORIBA Veterinary Adds New Rapid PCR Test for Difficult to Diagnose Parasite.
  • 13.3.17. ValitaCell Joins Beckman Coulter Life Sciences.
  • 13.3.18. Global Access Diagnostics Acquires Manufacturing Rights for IT-LEISH Rapid Diagnostic Test From Bio-Rad Laboratories.
  • 13.3.19. SSI Diagnostica Continues a Strong Growth Journey.
  • 13.3.20. BD, Accelerate Diagnostics Announce Global Commercial Collaboration.
  • 13.3.21. SGS Launched New Microbiology Laboratory In Phoenix, Arizona.
  • 13.3.22. Israel: EUR 22 Million (Usd 24.26 Million) EU Backing for Israeli Microbiology Diagnostic Player Pocared.
  • 13.3.23. DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics.
  • 13.3.24. bioMerieux Strengthens its Commitment to Fight Antimicrobial Resistance with the Acquisition of Specific Diagnostics, An Innovative Company Focusing on Fast AST Solutions.
  • 13.3.25. NIH Funded New Tuberculosis Research Advancement Centers.
  • 13.3.26. Raue Advises Sonic Healthcare on the Acquisition of Diagnosticum Laboratory Group.
  • 13.3.27. ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN.
  • 13.3.28. Hardy Diagnostics Now Offers the BioCode MDx-3000.
  • 13.3.29. Merck Announced Organizational Transformation of Life Science Business Sector To Strengthen Cdmo Offering And Accelerate Future Growth.
  • 13.3.30. COPAN Diagnostics Announces Another Giant Step in the Evolution of Artificial Intelligence in Clinical Microbiology.

Companies Mentioned

• 1. ELITech Group
• 2. Beckman Coulter, Inc.
• 3. Agilent Technologies, Inc.
• 4. Thermo Fisher Scientific Inc.
• 5. Rapid Micro Biosystems, Inc.
• 6. Kyokuto Pharmaceutical Industrial Co., Ltd.
• 7. Hardy Diagnostics
• 8. SSI Diagnostica A/S
• 9. QIAGEN N.V.
• 10. Merck KGaA
• 11. F. Hoffmann-La Roche Ltd.
• 12. Liofilchem S.r.l.
• 13. 3M Company
• 14. Bio-Rad Laboratories, Inc.
• 15. bioMerieux S.A.
• 16. Abbott Laboratories
• 17. COPAN Diagnostics Inc.
• 18. Cardinal Health, Inc.
• 19. Vircell S.L.
• 20. TCS Biosciences Ltd.
• 21. Clinichem Ltd.
• 22. Advanced Instruments, LLC
• 23. B. Braun SE
• 24. Pro Lab Diagnostics Inc.
• 25. Prestige Diagnostics U.K. Ltd.
• 26. Laboratorios Conda, S.A.
• 27. Becton, Dickinson and Company
• 28. Shimadzu Corporation
• 29. HORIBA, Ltd.
• 30. Diagnostica Longwood S.L.